Alnylam Pharmaceuticals annual capital expenditures (capex)
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Alnylam Pharmaceuticals Capital Expenditures (CapEx) Growth & History (ALNY)
Alnylam Pharmaceuticals's capital expenditures (capex) was $58.7M for fiscal 2025.
View full Alnylam Pharmaceuticals company overviewAlnylam Pharmaceuticals annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $58.7M | $24.4M | +71.24% |
| 2024 | 2024-12-31 | $34.3M | −$27.9M | −44.90% |
| 2023 | 2023-12-31 | $62.2M | −$9.8M | −13.67% |
| 2022 | 2022-12-31 | $72.1M | −$4.3M | −5.65% |
| 2021 | 2021-12-31 | $76.4M | $6.0M | +8.54% |
| 2020 | 2020-12-31 | $70.4M | −$69.8M | −49.80% |
| 2019 | 2019-12-31 | $140.2M | $13.3M | +10.46% |
| 2018 | 2018-12-31 | $126.9M | $22.7M | +21.76% |
| 2017 | 2017-12-31 | $104.2M | $39.7M | +61.42% |
| 2016 | 2016-12-31 | $64.6M | $51.6M | +398.51% |
| 2015 | 2015-12-31 | $12.9M | $4.0M | +44.52% |
| 2014 | 2014-12-31 | $9.0M | $5.0M | +123.69% |
| 2013 | 2013-12-31 | $4.0M | −$4.3M | −52.01% |
| 2012 | 2012-12-31 | $8.3M | $7.1M | +546.63% |
| 2011 | 2011-12-31 | $1.3M | −$3.4M | −72.72% |
| 2010 | 2010-12-31 | $4.7M | −$217,000 | −4.38% |
| 2009 | 2009-12-31 | $4.9M | −$5.8M | −54.02% |
| 2008 | 2008-12-31 | $10.8M | — | — |
Alnylam Pharmaceuticals quarterly capital expenditures (capex)
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $34.7M | $20.4M | +142.64% |
| Q1 2026 | 2026-03-31 | $21.8M | $12.9M | +143.40% |
| Q4 2025 | 2025-12-31 | $23.3M | $14.2M | +156.12% |
| Q3 2025 | 2025-09-30 | $12.1M | $8.0M | +189.65% |
| Q2 2025 | 2025-06-30 | $14.3M | $6.3M | +78.26% |
| Q1 2025 | 2025-03-31 | $9.0M | −$4.0M | −30.86% |
| Q4 2024 | 2024-12-31 | $9.1M | −$6.2M | −40.60% |
| Q3 2024 | 2024-09-30 | $4.2M | −$12.9M | −75.47% |
| Q2 2024 | 2024-06-30 | $8.0M | −$7.9M | −49.63% |
| Q1 2024 | 2024-03-31 | $13.0M | −$918,000 | −6.61% |
| Q4 2023 | 2023-12-31 | $15.3M | −$6.3M | −29.24% |
| Q3 2023 | 2023-09-30 | $17.1M | $582,000 | +3.53% |
| Q2 2023 | 2023-06-30 | $15.9M | −$136,000 | −0.85% |
| Q1 2023 | 2023-03-31 | $13.9M | −$4.0M | −22.22% |
| Q4 2022 | 2022-12-31 | $21.6M | −$251,000 | −1.15% |
| Q3 2022 | 2022-09-30 | $16.5M | −$9.6M | −36.65% |
| Q2 2022 | 2022-06-30 | $16.1M | $4.8M | +42.76% |
| Q1 2022 | 2022-03-31 | $17.9M | $681,000 | +3.96% |
| Q4 2021 | 2021-12-31 | $21.9M | $218,000 | +1.01% |
| Q3 2021 | 2021-09-30 | $26.1M | $13.6M | +109.87% |
| Q2 2021 | 2021-06-30 | $11.2M | −$5.4M | −32.49% |
| Q1 2021 | 2021-03-31 | $17.2M | −$2.4M | −12.43% |
| Q4 2020 | 2020-12-31 | $21.7M | −$17.1M | −44.16% |
| Q3 2020 | 2020-09-30 | $12.4M | −$23.6M | −65.56% |
| Q2 2020 | 2020-06-30 | $16.7M | −$4.6M | −21.59% |
| Q1 2020 | 2020-03-31 | $19.6M | −$24.4M | −55.47% |
| Q4 2019 | 2019-12-31 | $38.8M | $1.3M | +3.44% |
| Q3 2019 | 2019-09-30 | $36.1M | −$9.4M | −20.59% |
| Q2 2019 | 2019-06-30 | $21.2M | −$1.5M | −6.45% |
| Q1 2019 | 2019-03-31 | $44.0M | $22.8M | +107.22% |
| Q4 2018 | 2018-12-31 | $37.5M | $16.8M | +80.98% |
| Q3 2018 | 2018-09-30 | $45.4M | $19.7M | +76.84% |
| Q2 2018 | 2018-06-30 | $22.7M | $1.1M | +4.88% |
| Q1 2018 | 2018-03-31 | $21.3M | −$14.9M | −41.20% |
| Q4 2017 | 2017-12-31 | $20.7M | $849,000 | +4.27% |
| Q3 2017 | 2017-09-30 | $25.7M | $5.4M | +26.51% |
| Q2 2017 | 2017-06-30 | $21.7M | $30,000 | +0.14% |
| Q1 2017 | 2017-03-31 | $36.2M | $33.4M | +1210.33% |
| Q4 2016 | 2016-12-31 | $19.9M | $16.8M | +541.46% |
| Q3 2016 | 2016-09-30 | $20.3M | $13.8M | +213.39% |
| Q2 2016 | 2016-06-30 | $21.6M | $20.4M | +1610.52% |
| Q1 2016 | 2016-03-31 | $2.8M | $649,000 | +30.76% |
| Q4 2015 | 2015-12-31 | $3.1M | −$427,000 | −12.11% |
| Q3 2015 | 2015-09-30 | $6.5M | $3.3M | +102.72% |
| Q2 2015 | 2015-06-30 | $1.3M | −$588,000 | −31.75% |
| Q1 2015 | 2015-03-31 | $2.1M | $1.7M | +443.81% |
| Q4 2014 | 2014-12-31 | $3.5M | $2.6M | +301.59% |
| Q3 2014 | 2014-09-30 | $3.2M | $2.2M | +236.32% |
| Q2 2014 | 2014-06-30 | $1.9M | $1.5M | +388.65% |
| Q1 2014 | 2014-03-31 | $388,000 | −$1.4M | −78.43% |
| Q4 2013 | 2013-12-31 | $878,000 | $192,000 | +27.99% |
| Q3 2013 | 2013-09-30 | $950,000 | −$4.8M | −83.42% |
| Q2 2013 | 2013-06-30 | $379,000 | −$1.3M | −77.31% |
| Q1 2013 | 2013-03-31 | $1.8M | $1.5M | +584.03% |
| Q4 2012 | 2012-12-31 | $686,000 | $162,000 | +30.92% |
| Q3 2012 | 2012-09-30 | $5.7M | $5.5M | +2061.89% |
| Q2 2012 | 2012-06-30 | $1.7M | $1.2M | +252.32% |
| Q1 2012 | 2012-03-31 | $263,000 | $235,000 | +839.29% |
| Q4 2011 | 2011-12-31 | $524,000 | −$614,000 | −53.95% |
| Q3 2011 | 2011-09-30 | $265,000 | −$802,000 | −75.16% |
| Q2 2011 | 2011-06-30 | $474,000 | −$956,000 | −66.85% |
| Q1 2011 | 2011-03-31 | $28,000 | −$1.1M | −97.45% |
| Q4 2010 | 2010-12-31 | $1.1M | — | — |
| Q3 2010 | 2010-09-30 | $1.1M | $330,000 | +44.78% |
| Q2 2010 | 2010-06-30 | $1.4M | — | — |
| Q1 2010 | 2010-03-31 | $1.1M | — | — |
| Q3 2009 | 2009-09-30 | $737,000 | — | — |
Alnylam Pharmaceuticals capital expenditures (capex) trends
Over the last five fiscal years, Alnylam Pharmaceuticals's capital expenditures (capex) decreased from $70.4M to $58.7M, a change of −$11.7M. The latest reported quarter, Q2 2026, shows $34.7M.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alnylam Pharmaceuticals source filings ↗